Quorum Review IRB Establishes an East Coast Ethics Board Focused on Oncology
Quorum Review IRB
is introducing a new ethics board located in Cambridge, Massachusetts. This panel includes members from academia with significant expertise in oncology research. The Cambridge Board will begin reviewing studies on October 4, 2011. Quorum will continue to hold eight board meetings each week.
Oncology is a complex, fast-moving, and innovative area of clinical research. With this panel, researchers can benefit from IRB members with years of experience in oncology treatment and research. Quorum’s broad range of therapeutic expertise will also be supported as members are affiliated with a range of institutions, including Harvard Medical School, Dana Farber, Tufts, and Boston University.
The Cambridge Board will meet weekly. Researchers may also submit oncology studies to the next available Board meeting, as Quorum always includes oncology expertise on a panel when a cancer study is presented for review.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
